Health Care • Medical/Dental Instruments
$0.54 ▼ -0.02
(-3.60%)
MKT CAP: $2.5M • VOL: 119.4K
52W L $2 52W H $98
ROARABLE / RQD
D- • 43/100
PIOTROSKI
5 / 9
IVF // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.8M | $6.6M | $3.0M |
| YoY Revenue Growth % | +4.3% | +117.2% | — |
| Gross Profit | $6.8M | $2.8M | — |
| Gross Margin % | 98.0% | 43.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.2M | -$6.6M | -$6.8M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | $23.3M | $9.1M | $8.0M |
| EBITDA (Normalized) | -$7.2M | -$6.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.0M | -$3.0M | -$4.8M |
| Capital Expenditures (CapEx) | $43.4K | $183.7K | — |
| Free Cash Flow (FCF) | -$7.1M | -$3.2M | -$4.8M |
| FCF Margin % | -80.0% | -48.1% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -38.2% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | $744.7K | $1.1M | — |
| Total Stockholders' Equity | $7.2M | $12.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IVF.